Hey readers! Here's a quirk that trips up even careful clinicians: the antibody test we lean on most to catch celiac disease can quietly fail the very patients who need it. If you or your child carries selective IgA deficiency, the standard IgA-based screen can read reassuringly normal while the gut is anything but. This issue is your map through that blind spot, plus the diagnostics, trials, and safety alerts worth your attention right now. Let's dig in.
🔬 The IgA-deficiency blind spot
Selective immunoglobulin A deficiency and celiac disease: Immune response dynamics is the study to bookmark this month. This pan-European ESPGHAN registry analysis followed pediatric patients who have both selective IgA deficiency (SIgAD) and celiac disease, tracking their IgG antibody behavior after starting a gluten-free diet.
The headline for practitioners is a hard rule about diagnosis. In children with SIgAD, the researchers found the numbers on a serology report simply don't track with what's happening in the gut.
At diagnosis, there is no correlation between mucosal damage and serological levels and a small bowel biopsy is mandatory to confirm CeD in children with SIgAD.
So if you're a parent whose IgA-deficient child got a "celiac ruled out" based on antibody numbers alone, that's worth a second conversation. The biopsy isn't optional here; it's the confirmation step the antibody screen can't substitute for.
The follow-up findings matter just as much. After starting a gluten-free diet, IgG antibodies fall slowly in these patients, with 50% still testing serology positive after three years. Normalization drags out even longer for IgG-class anti-transglutaminase antibodies (IgG-TGA), especially when baseline levels start above ten times the upper limit of normal. And crucially, early antibody movement did not predict where things eventually landed.
The practical takeaway: don't hang a decision about a repeat scope purely on how the follow-up antibody trend looks, particularly for kids who started with very high IgG-TGA. Slow-to-normalize numbers in this group are the expected pattern, not automatically a red flag of ongoing exposure.
🦠 Why IgA deficiency and celiac travel together
If the clinical study above tells you what to do about IgA-deficient patients, this next one offers a hint at why the two conditions cluster in the first place. Gut Bacterium Linked to Gluten Sensitivity, Study Finds reports a mouse study in Gut Microbes where gluten only caused intestinal damage when secretory IgA was missing and a specific bacterium was present.
Only the gluten-fed, bacteria-colonized mice developed villus blunting, along with an expansion of several inflammatory T-cell types, including Th17 and CD8+ cells.
Mono-colonizing germ-free mice with a single species, Streptococcus lutetiensis, was enough to trigger gluten-induced damage. That points to a diet-microbe interaction rather than gluten acting alone.
A firm caveat before anyone over-reads this: it's a single-lab mouse model, the damage showed up in the ileum rather than the human duodenum, and it did not directly test celiac disease. Still, it's a genuinely interesting mechanistic thread that could help explain the long-observed link between IgA deficiency and higher celiac risk. - Biome Sci
🧫 New antibody diagnostics on the market
Since antibody testing is the theme this issue, two lab-side developments are worth logging even if they aren't celiac-specific.
Aptiva APS IgA: FDA 510(k), 3 Isotypes - Werfen announced on September 23, 2026 that its Aptiva antiphospholipid syndrome IgA reagent received FDA 510(k) clearance and a CE Mark under IVDR, completing an IgA/IgG/IgM panel. It's a reminder that IgA-isotype assays keep expanding across autoimmune diagnostics; note the release didn't include performance figures or a 510(k) number. - NovaPharma News
New Study Finds Gut Bacteria and Metabolic Changes in Children With Celiac Disease - A small study found that untreated celiac in children came with specific bacterial and metabolic shifts (notably Bacteroides ovatus and changes in butyrate) rather than a wholesale loss of diversity. Tellingly, after six months gluten-free, antibody levels fell in all retested children but four still sat above the normal range, echoing that slow-normalization theme. - Celiac.com
The findings suggest that looking at what gut bacteria are doing, rather than simply counting which bacteria are present, may provide important clues about celiac disease and recovery after gluten is removed from the diet.
💊 Drugs in the pipeline
The gluten-free diet remains the only treatment, but several antibody-based therapies are moving through trials.
Teva's Lab-Made Antibody Shot for Celiac Shows Hopeful Results covers TEV '408, an anti-IL-15 monoclonal antibody. In a 50-adult Phase 2a study, participants on a gluten-free diet got the drug or placebo, then a daily gluten challenge equal to a standard slice of bread (3 grams of gluten) for six weeks. Teva reports lower villous-height loss and lower GI symptom scores versus placebo.
Could Teva's New Drug Protect Against Accidental Gluten? adds the sober context you want before getting excited: these are sponsor-reported topline numbers, not a peer-reviewed publication or approval.
That clears a bar the previous anti-IL-15 drug missed. But it's sponsor-reported topline data from a small study, not a published trial, not an approval, and not a reason to relax the diet.
On the other side of a different trial, "I hope it helps millions": Belfast woman first in UK to trial new celiac disease drug profiles Caroline Clarke, the first UK patient recruited into the early-phase international ANB033-101 study at the Ulster Hospital. About 60 participants worldwide will receive three subcutaneous doses of investigational medicine or placebo, with endoscopies before and after.
The hope is that this research will benefit patients with coeliac disease in the future. Obviously this is an early-stage trial and it may take time before any potential treatment becomes available to patients.
- Dr Grant Caddy, via Belfast Live. For patients still symptomatic despite a strict diet, trials like this are a concrete option worth asking your gastroenterology team about.
⚠️ On your plate this week
Mixes Made with Certified Gluten-Free Plantain Flour Tested Far Above FDA Gluten Limit is the safety alert to act on. GF Blends recalled three products (Truly AIP All Purpose Flour, Truly AIP Bread Mix, and EAT G.A.N.G.S.T.E.R. Flat Bread Pizza Mix) after independent testing found gluten well above the FDA's 20 parts per million limit. The contamination traced to certified gluten-free plantain flour from supplier PMF Global. Check your pantry against the lot numbers in the FDA notice and return affected items for a refund. - Medical Daily
For people with celiac disease, gluten damages the lining of the small intestine, and a gluten-free label is often their main safeguard.
And a finding that reframes how we think about "safe" exposure: How Much Gluten Is Too Much? New Study Finds Celiac Immune Reaction at Just 3 mg reports an Australian trial in Gastroenterology where 17% of adults reacted immunologically at 3 mg of gluten. Just as important for daily life, symptoms didn't reliably signal exposure at low doses.
Feeling fine after a restaurant meal doesn't guarantee you weren't exposed. And the reverse is true too, since an upset stomach doesn't automatically mean you were glutened.
On the living-gluten-free front: when you're navigating restaurants or travel and want to cut down on cross-contact risk, the crowd-sourced reviews on Find Me Gluten Free (findmeglutenfree.com) are a practical way to vet spots ahead of time. We're not sponsored by them; it's just a resource plenty of readers find genuinely useful.
🧪 Also worth a glance
Grape seed compound reduced gluten-linked intestinal stress in mice - Grape seed procyanidins eased gliadin-induced epithelial stress in cells and mice, with ATF4 as a key mediator. No human testing yet, so file it as early mechanism, not advice. - Vinetur
Global consensus backs T1D screening from age 2 - A new Diabetologia consensus recommends islet autoantibody screening in children starting ages 2-4. Relevant to celiac families given the autoimmune overlap; the parallel push toward early antibody screening across autoimmune conditions is a trend worth watching. - The Limbic
That's the issue. If there's one thing to carry forward, it's this: in IgA-deficient patients, a normal-looking antibody report is not a green light, and the biopsy still rules. Take care of yourselves and each other.